PROGNOSTIC VALUE OF CELL-PROLIFERATION IN BREAST-CANCER AS DETERMINED BY PROLIFERATING CELL NUCLEAR ANTIGEN (PCNA) IMMUNOSTAINING

A series of 175 biopsies from primary tumours were subjected to immunostaining for proliferatin cell nuclear antigen (PCNA) and histopathological analysis for prognostic factors in 175 women with breast cancer followed up for nine years. In normal breast epithelium, only occasional nuclei were positive for PCNA. In breast carcinomas, the fraction of nuclei positive for PCNA showed considerable intratumoural variation, usually being highest at the invasive tumour margins. The fraction of positive nuclei was significantly related to histological grade (p<0.001), histological type (p=0.049) and tumor recurrence (p=0.01). The fraction of positive nuclei predicted recurrence-free survival (p=0.007) and overall survival (p=0.0158) in univariate analysis. In the multivariate analysis including also the standard prognostic factors, the PCNA positivity predicted recurrence-free survival (p=0.004) and overall survival (p=0.030) independently. The results show that the light microscopic assessment of the growth fraction as determined by PCNA immunolabeling has independent prognostic value in breast carcinomas like some other (e.g. S phase fraction, mitotic index, Ki-67) previously characterized proliferation indices.